| Vol. 10.26 – 5 July, 2022 |
| |
|
|
| Using single-cell sequencing combined with isolation of specific antibodies, the authors found that in two healthy donors, the memory B cell repertoire was dominated by large IgM, IgA, and IgG2 clonal families, whereas IgG1 families, including those specific for recall antigens, were of small size. [Nature Immunology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists presented a case of bone marrow failure in a 57-year old man with diffuse large B cell lymphoma (DLBCL)-type Richter transformation receiving tisagenlecleucel in a standard-of-care setting. [Blood] |
|
|
|
| Researchers cultured regionally annotated glioblastoma explants in perfusion bioreactors to assess immune tumor microenvironment responses to immunotherapy. [Science Advances] |
|
|
|
| Investigators reported therapeutic synergies of targeted cytotoxic auristatin radiosensitization to stimulate anti-tumor immune responses providing a rationale for clinical translational of auristatin antibody drug conjugates with radio-immunotherapy combinations to improve tumor control. [Nature Communications] |
|
|
|
| The authors used CD1a tetramers to show that CD1a was a ligand for Vδ1+ γδ T cells. Functional studies suggested that two γδ T cell receptors bound CD1a in a lipid-independent manner. [Nature Communications] |
|
|
|
| Researchers demonstrated that major histocompatibility complex (MHC):T cell antigen receptor signaling could be required to initiate a cancer phenotype from an understudied developmental state that appeared to be represented in the mouse and human disease spectrum. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists conducted a global study at Tertiary Cancer Centres and collected data of patients with mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer treated with anti-programmed-death (PD)-1 monotherapy or anti-PD-1/anti- cytotoxic T-lymphocyte antigen 4 combination. [European Journal of Cancer] |
|
|
|
| The authors identified a set of 3′ UTR targeting lymphocyte cytosolic protein 2 (LCP2) antisense oligonucleotides, which knocked down LCP2 in a human T cell line and primary human T cells and found that these suppressed T cell receptor mediated activation. [Journal of Autoimmunity] |
|
|
|
| Researchers examined the immunomodulatory properties of essential oil obtained from the Nigella sativa seeds by hydrodistillation and its two main constituents: thymoquinone and p-cymene. [Biomedicine & Pharmacotherapy] |
|
|
|
| GPR87 expression in LUAD was positively correlated with immune infiltration. In addition, GPR87 expression was associated with immune and chemotherapy resistance in lung adenocarcinoma patients. [Communications Biology] |
|
|
|
| The authors described a lipidic peptide, designated IK14004, that modified crosstalk between T cells and dendritic cells resulting in suppression of IL-12p40/IFN-γ production. [Scientific Reports] |
|
|
|
| Scientists investigated the utility of the cytokine levels in serum and urine as biomarkers, the role of non-functional isoforms, and the association of gene variants with systemic lupus erythematosus. [Scientific Reports] |
|
|
|
| Glycoprotein A dominant repeat (GARP) expression on T cells from peripheral blood and bronchoalveolar lavage collected from patients with chronic obstructive pulmonary disease (COPD) was examined by flow cytometry. [Respiratory Research] |
|
|
|
|
| The authors summarize the key steps in the development of immunotherapies for mesothelioma, focusing on strategies that have led to randomized clinical evaluation and emerging predictors of response. [Nature Reviews Clinical Oncology] |
|
|
|
| Scientists focus on T cell reactions and discuss recent advances in disease pathogenesis by exploring the impact of tolerance mechanisms in determining susceptibility in genetically predisposed patients. [Current Opinion in Allergy and Clinical Immunology] |
|
|
|
| The authors focus on recent developments in immunotherapy combinations and reflect on how combinations should be optimized to maximize the impact of immunotherapy in clinical oncology. [Nature Cancer] |
|
|
|
|
| Vertex Pharmaceuticals announced that the US FDA has lifted the clinical hold placed on the Phase I/II clinical trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. [Vertex Pharmaceuticals Incorporated] |
|
|
|
| Skyhawk Therapeutics, Inc. announced the signing of an exclusive worldwide collaboration agreement with Sanofi to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. [Skyhawk Therapeutics, Inc.] |
|
|
|
| BriaCell Therapeutics Corp. has entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison, to manufacture Bria-Pros™, BriaCell’s off-the-shelf personalized immunotherapy for prostate cancer, for anticipated use in clinical studies. [BriaCell Therapeutics Corp.] |
|
|
|
|
| November 16 – 18, 2022 Melbourne, Victoria, Australia |
|
|
|
|
|
| Georgia Institute of Technology – Atlanta, Georgia, United States |
|
|
|
| University of Maryland School of Medicine – Baltimore, Maryland, United States |
|
|
|
| Philipps University of Marburg – Marburg, Germany |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| University of Gothenburg – Gothenburg, Sweden |
|
|
|
|